BACKGROUND: The DBA/2J mouse spontaneously develops ocular hypertension and time-dependent progressive retinal ganglion cell (RGC) loss. This study examines changes in amino acid levels in the vitreous, and changes in the expression of retinal glutamate transporters and receptors that occur during the progression of this pathology. METHODS: Retinas were obtained from DBA/2J mice at ages 3, 6 and 11 months. C57BL/6 mice were used as age-matched controls. Vitreal amino acid content was measured with HPLC. Western blotting and immunohistochemistry were performed using specific antibodies against the glutamate transporters (GLAST, GLT-1v, EAAC-1) and glutamate receptors, particularly NMDA (NR1, NR2A, NR2B) and AMPA (GluR1, GluR2/3, GluR4) receptors. RESULTS: HPLC showed retinal concentrations of glutamate, glutamine, glycine, alanine, lysine, serine, and arginine to be significantly higher in DBA/2J mice at 11 months of age compared to age-matched controls. Western Blots revealed a moderate decrease of GLAST and GLT-1v expression in DBA/2J mice at 6 and 11 months as compared to age-matched controls while there was no change in EAAC1. Immunohistochemically, no changes in expression of NMDA and AMPA receptors were seen. CONCLUSION: Alterations of amino acid content and enhanced glutamate neurotransmission might be involved in the pathogenesis of retinal neurodegeneration in the DBA/ 2J mouse model of ocular hypertension. Moreover, these mice provide an animal model for studying excitotoxic retinal damage.
BACKGROUND: The DBA/2J mouse spontaneously develops ocular hypertension and time-dependent progressive retinal ganglion cell (RGC) loss. This study examines changes in amino acid levels in the vitreous, and changes in the expression of retinal glutamate transporters and receptors that occur during the progression of this pathology. METHODS: Retinas were obtained from DBA/2J mice at ages 3, 6 and 11 months. C57BL/6 mice were used as age-matched controls. Vitreal amino acid content was measured with HPLC. Western blotting and immunohistochemistry were performed using specific antibodies against the glutamate transporters (GLAST, GLT-1v, EAAC-1) and glutamate receptors, particularly NMDA (NR1, NR2A, NR2B) and AMPA (GluR1, GluR2/3, GluR4) receptors. RESULTS: HPLC showed retinal concentrations of glutamate, glutamine, glycine, alanine, lysine, serine, and arginine to be significantly higher in DBA/2J mice at 11 months of age compared to age-matched controls. Western Blots revealed a moderate decrease of GLAST and GLT-1v expression in DBA/2J mice at 6 and 11 months as compared to age-matched controls while there was no change in EAAC1. Immunohistochemically, no changes in expression of NMDA and AMPA receptors were seen. CONCLUSION: Alterations of amino acid content and enhanced glutamate neurotransmission might be involved in the pathogenesis of retinal neurodegeneration in the DBA/ 2J mouse model of ocular hypertension. Moreover, these mice provide an animal model for studying excitotoxic retinal damage.
Authors: S W John; R S Smith; O V Savinova; N L Hawes; B Chang; D Turnbull; M Davisson; T H Roderick; J R Heckenlively Journal: Invest Ophthalmol Vis Sci Date: 1998-05 Impact factor: 4.799
Authors: Michael R Steele; Denise M Inman; David J Calkins; Philip J Horner; Monica L Vetter Journal: Invest Ophthalmol Vis Sci Date: 2006-03 Impact factor: 4.799
Authors: Richard T Libby; Michael G Anderson; Iok-Hou Pang; Zachary H Robinson; Olga V Savinova; I Mihai Cosma; Amy Snow; Lawriston A Wilson; Richard S Smith; Abbot F Clark; Simon W M John Journal: Vis Neurosci Date: 2005 Sep-Oct Impact factor: 3.241
Authors: C K Vorwerk; R Naskar; F Schuettauf; K Quinto; D Zurakowski; G Gochenauer; M B Robinson; S A Mackler; E B Dreyer Journal: Invest Ophthalmol Vis Sci Date: 2000-10 Impact factor: 4.799
Authors: Sebastian Thaler; Robert Rejdak; Karen Dietrich; Thomas Ladewig; Etsuo Okuno; Tomasz Kocki; Waldemar Andrzej Turski; Anselm Junemann; Eberhart Zrenner; Frank Schuettauf Journal: Mol Vis Date: 2006-02-22 Impact factor: 2.367
Authors: Laura Fernández-Sánchez; Luis Pérez de Sevilla Müller; Nicholas C Brecha; Nicolás Cuenca Journal: Invest Ophthalmol Vis Sci Date: 2014-08-12 Impact factor: 4.799
Authors: Sylvia Bolz; Frank Schuettauf; Julia E Fries; Sebastian Thaler; Andreas Reichenbach; Thomas Pannicke Journal: Graefes Arch Clin Exp Ophthalmol Date: 2008-06-11 Impact factor: 3.117
Authors: Chan Kee Park; Jiook Cha; Soo Chul Park; Phil Young Lee; Jie Hyun Kim; Hwa Sun Kim; Shin Ae Kim; In-Beom Kim; Myung-Hoon Chun Journal: Exp Brain Res Date: 2009-06-24 Impact factor: 1.972
Authors: Rossella Russo; Federica Cavaliere; Giuseppe Pasquale Varano; Marco Milanese; Annagrazia Adornetto; Carlo Nucci; Giambattista Bonanno; Luigi Antonio Morrone; Maria Tiziana Corasaniti; Giacinto Bagetta Journal: PLoS One Date: 2013-08-06 Impact factor: 3.240